Levosimendan in pulmonary hypertension and right heart failure

Pulmonary Circulation - Tập 8 Số 3 - Trang 1-7 - 2018
Mona Sahlholdt Hansen1, Asger Andersen1, Jens Erik Nielsen‐Kudsk1
1Department of Cardiology, Institute of Clinical Medicine, Aarhus University Hospital, Denmark

Tóm tắt

Pulmonary hypertension is a multifactorial disease with a high morbidity and mortality. Right ventricular function is the most important predictor of morbidity and mortality in patients suffering from pulmonary hypertension, but currently there are no approved treatments directly supporting the failing right ventricle. Levosimendan is a calcium sensitizing agent with inotropic, pulmonary vasodilatory, and cardioprotective properties. Given its pharmacodynamic profile, levosimendan could be a potential novel agent for the treatment of right ventricular failure caused by pulmonary hypertension. The aim of this review is to provide an overview of the current knowledge on the effects of levosimendan in pulmonary hypertension and right heart failure.

Từ khóa


Tài liệu tham khảo

10.1183/13993003.01032-2015

10.1183/09031936.00139009

Ibrahim BS. Right ventricular failure.E‐J Cardiol Pract2016; 14(32).

10.1016/S0014-2999(97)01362-9

10.1067/mcp.2000.110972

10.1097/00005344-199505000-00016

10.1016/S0014-2999(97)01108-4

10.1007/s10741-008-9128-4

10.1097/00005344-200104000-00003

10.1111/j.1527-3466.2005.tb00158.x

10.5414/CPP40465

10.1016/j.rec.2016.11.005

Mebazaa A, 2003, Levosimendan: a new dual‐action drug in the treatment of acute heart failure, Int J Clin Pract, 57, 410, 10.1111/j.1742-1241.2003.tb10517.x

10.1001/jama.297.17.1883

10.1016/j.jchf.2012.12.004

10.1097/00000539-200206000-00009

10.1097/01.CCM.0000242157.19347.50

10.1097/01.CCM.0000275266.33910.8D

10.1097/01.CCM.0000257326.96342.57

10.1007/s00134-011-2144-1

10.1097/FJC.0b013e31824938f0

10.1111/j.1399-6576.2011.02436.x

10.1097/01.CCM.0000084844.95073.C0

10.1007/s00134-011-2254-9

10.1086/677366

10.1097/FJC.0000000000000349

10.1055/s-0033-1355444

10.1097/FJC.0000000000000508

10.1177/2045893217743122

10.1177/0091270008325150

Martynyuk TV, 2012, Possibilities of using levosimendan in patients with idiopathic pulmonary hypertension, Terapevticheskii Arkhiv, 84, 83

10.1111/crj.12699

10.2459/JCM.0b013e32832aa873

10.1093/eurheartj/ehv512

10.1016/j.amjcard.2006.06.052

10.1097/CCM.0b013e3181b0314a

10.1161/01.CIR.102.18.2222

10.5603/KP.2013.0258

10.1007/s00059-008-3051-2

10.1007/s00380-008-1077-2

10.1111/j.1742-1241.2007.01510.x

10.1053/j.jvca.2016.01.015

10.1097/01.PCC.0000137355.01277.9C

10.1038/pr.2012.154

10.1007/s00540-012-1537-9

10.1097/01.PCC.0000253026.67341.5D

10.1016/j.ejcts.2004.03.034

10.1007/s00392-004-0053-9

Schwienbacher M, 2013, Heart transplantation in a 14‐year‐old boy in the presence of severe out‐of‐proportion pulmonary hypertension due to restrictive left heart disease: a case report, Case Rep Cardiol, 2013, 418565

10.1016/j.ijcard.2015.03.426

10.1097/01.CCM.0000230244.17174.4F

10.1177/0310057X0703500518

Pitsiou G, 2013, Inhaled iloprost plus levosimendan to decompensate right heart failure due to chronic thromboembolic pulmonary hypertension, Anaesth Intensive Care, 41, 554

Thông tin
Thông tin xuất bản

Pulmonary Circulation

Tập 8 Số 3

1-7

Thông tin tác giả